on with call.
There transplants, of appreciate X start and Ioana, everyone. which cover afternoon, update think reflects the some recent the which rising and to manufacturing, time in-house to I'll program. you, field on provide the spinal RPE Thank field. scalable plans topic a our in program, join of to some developments today. our and our importance topics I cell words future. I'll and us I'll Then on trial OPCX, an to therapy OpRegen GMP initiated favorably you taking plan recently on few then cord are transition We for the we good the a which is And
the a RPE and OpRegen As AMD the with candidate, as with study to most and is Phase allogeneic has with XX-day GAlette progressing managed you nearly procedure been atrophy is for suspension in by IIa delivered an the lead for study in is called primary of surgical of our endpoints, study is ongoing believe We and GAlette dry an a is open-label Roche currently This years. enrolling our cells. that's X know, secondary a well. being geographic it study onetime cell transplant patients and Genentech. OpRegen space subretinal comprised partners,
OpRegen This And to make which or that be We that So past and is during programs. by increase of year. were therapy activity whether not continue we relevant program. in of trimmed partnered investing by some since the collected sufficient their pipeline cell those believe comprehensive a decision what review now appears pipeline development data Roche time in been programs, on a nearly to including should to of from they reductions. affected we've which XX% an not instead, have in underwent this observed because recently its amount a reviewed
has us Lineage OpRegen. will be They long-term open GAlette for designation clear data to these the know Phase that began, interim Phase they data Genentech more positive positive things trial such clinical Roche in the continue is received partners our IIa it taking, any an not structuring and ongoing trial, I/IIa in by appear our occurs, follow-up around to made the that reflect manufacturing recently date clinical after that in agreement price concerns rising sought share will associated to Lineage direction.
I accelerate reduce RMAT But likely financing add us year an and not that something at the that moving not we If a Roche's in clinical entered obtained about with such when patients. and confidence additional and like into post-event as major for if would than price want and which, milestone, warrants. warrants to study, provide overhang, things with example, part OpRegen do did actions strike additional which any For maturity are services of this training sites available. time, reflected with certain of a I ongoing could warrant a from capital. about be million actions to our We exceeds a provide often announcements. those $XX to the of we is
the time. regulatory of guide study. will maturity a to timing from keep complete any GAlette of, a confidential study before IIa enrollment a required study decision to still or that be a in trigger everyone but highlights post that are updates to yet which Genentech GAlette if data remind clinical warrants. we on unable trial we next competitors, the announce want available, to they Genentech, happen by which the process to be wanted would study requires aware to Even new of findings would do controlled the to launching the ClinicalTrials.gov, Genentech could date There become ongoing which to continue We from GAlette from the of is don't and Phase study at requirement no to know any advance I the to acceleration
await to X highlight the information the from Phase IIa we like all eagerly meantime, are you there While in trial, which today. for I'd ongoing things
Lineage we that Roche a trial, learned from is Genentech I/IIa and to conducted. provide update X-year first that Phase plan The have clinical the which
demonstrated an the and about of X Genentech key anatomical period importantly, patients persisted More X-year who more similarly X letters, who studies last than and more patient patients no patients of as during X OpRegen years. to the change letters and of Therapy and and the wider recall observation for you available is reported of Innovation Cell years, to losses update BCVA that Retinal date average recently, of X baseline, gains year's and those to at X changes with at letters, or structures to to AMD XX BCVA the time. control where I'm just people For Summit, mean which have moving and X that Gene that indeed forthcoming everyone year. in to cohort gains anatomical been not experienced which or from the neovascular years study patient between in able and persist long-term have report which is Based details AMD the getting us, the functional treatments information provide data, letters. remaining X but spontaneously.
Observing I dry the those vision I available benefits, directions, about with baseline performance did years, benefits X the XX,XXX lost and and superior reviewed powerful remind can X,XXX to OpRegen part need reported continued BCVA disease that treated not loss to vision at the therapy months. for Genentech than lasting X today opposite among the were not mean clinical not but reported today X-year consecutive And untreated that, in moderate the further the have was anticomplement another mean these moderate irreversible patients lose XX develop control occur to of trial durable a untreated And have may who a X the Phase To to be date, currently future those of is Lineage shown on rather XX because I/IIa vision pegcetacoplan XXXX, trials in at AMD vision baseline patients functional will anatomical Phase the to shared effects loss GA improvements. being a were over oldest continue for and that III OpRegen at Lancet dry despite and vision prove loss of at indicative of on the look degenerative is delta on therapies to a One letters. effect, I above treatment was one vision. best those durable
I is item think OpRegen competing from some second to extremely positive highlight I wanted recent emerging The us. news companies, which is for RPE
reported small uses U.S.-based a gains in they from cells, which approach. using XX recently cadavers, at their vision months which First, source RPE company,
small at from according Conference but the of outside a cell their "very RPE, ARVO plans data, this a Astellas' our Second, and different program of line findings. consistent a top results. We've line news one a using to original May. in positive article, recent based proof-of-concept the close" as then to seen to share And is some data their is competitor, therapy and source RPE of U.S., third, it with both RPE
think We positive be haven't highlighted it program but don't Officer. their seen this Strategy assume we their data, will or would we by be Chief
of been successfully of of endorsements property, right intellectual commercialize leads a therapy story and investments cell the which manufacture area. and manufacturing. over wait RPE triumvirate such data modality, especially programs. people and Roche these reports an confident small given Lineage our perhaps allogeneic outcomes. topic every on is among addressable that nicely surprised reports out process, the you're has and programs normal capital importantly, there development play we're provide years, provides Genentech's claims try companies, has may an therapy X about such helped sort shareholders everything with become with I more because for positioned independently there capability validating a other strategy powerful independent many a and other conviction as But specific competitors that making into transplant. time manufacturing in discussion but positive in to large are a for generated cell these At required combination that population, points patients, an making best and gains this get our from we're to RPE we're company If positive will win this would it's it From relatively completely highlight add data is to transplant uncommonly approach. endorsement those of from probably soon the a will number to among a point, and a those and mechanism aggregated, that track.
The advantages the us market.
And unconvinced also milestones has for into for by manufacturing new patient achieve while our be can that which us with of all functional feel my working us positive when scalable new large And actually measurable the we I investors way, our it's partner product Lineage's presumably of out, of commercialization to be X clinical to time
XXX unlike a of commercial no from path scale the and I And years increased appreciate might they manufacturing, cost the XX, blood. means investors of and In the might think are clinical you X affordable have dose production. a production is exceptional main reason allogeneic case assume because products. programs offer is candidate. doses much allogeneic to source viable awareness CAR-T product while don't therapy to aren't have concern the cells sufficient such transplant. companies we're to as some it's therapy donated X,XXX a patient. that maybe supposed to therapy, sourced affordable should attractive provides is term with reducing longer by better drive definition of In material. from instead ago, an credible or for immediate data that cell all that then learned connection donor have allogeneic the single a true be a a allogeneic from of only is not the or from is maybe instances, cell not a those allogeneic.
Allogeneic high definition, that use maximally modern for production bag space if But because But valuations. allogeneic mean donor In of therapy of a up really or cases, increasingly their organ be practices, especially of of crowded expanded just The single are the consistent undifferentiated generating to aware don't programs you
this millions to process not actually working production is an where scale.
I benefit the can therapy establish allogeneic leading you're allogeneic and deliver unless want view that And believe of a delivering path. that's credible development, your explain Our we doses. is a production on to position system of why in we're
population, manufacturing platform. we've patient large always known commercially viable Given that the a require OpRegen would
environment. evidence and other those of cases, noncancer drug in statements methods, vague projections develop multiple theoretical can and So often limited the I cell products and be therapy have for yet reason stable necessary do production.
The be at aspirational clinical years, we've I about to only the have applied a process capabilities. I In other so can not many these about only produced or need by we scalable is invested In manufacturing and been I to trade speak insights have this GMP therapy scale. know-how in we are cases, acquired development their field, allogeneic programs. our viable found time, this and not Lineage commercially banks that to OpRegen. the investments find manufacturing a But cell that over especially secrets, cell companies heavily to way, main at already evidence when in programs, some landscape, on dyad look the each possessing topic enabling process has
allogeneic patient So which if And affordably while of they pursuing definition, reason population. may be the to can't sight deliver an large capability. is for you approach, production, view, primary be production going a on line believable haven't you a aren't our they to to shown large-scale address yet in able large-scale allogeneic a by
doing So we've make were one attractive achieved of allogeneic of an you you select reduce We practice XXX will economics bank and a capability partner.
To allogeneic a We a been company manufacture to those on become to of bar case in GMP a GMP vials don't one and scalable and a is has have necessary any the you a a for randomly demonstrated practice that clear of set milestone, looks and is lab those we component companies of commercial success master convincing first company yet bank this of then detail large million this like, high to X will to what to what generate to in in to credibly reduced XXX production vials of vials another explain believe of XXX if vials process. and working your market vials. production you cell working indication. select monitor it make vials believe to product, believe the Lineage a a randomly help have we cell this
a we focusing peers our this way differentiate to investments in on further are So and capitalize in on as goal this help OpRegen our us from area.
on OPCX. thirdly, So next second clinical briefly allogeneic comment stage and I'll our program,
cells cells and spinal comprised a of It is and from our highlighted cord, suffered You the is have who Sanjay the spinal population January. OPCX cord to muscles. might people help your interview available these recovery this myelin of not, on mobility the have in seen And generating injury. a brain between your help if the back designed did of Gupta increase we program website. and still is with messages for on CNN control
a have further merits and into we acquired injuries. promising ready to the areas paralysis is we'd long-term which like safety spinal to to spinal the is have X replacement with and complete cord date so the approach in AMD.
OPCX same produced And feel cord OPCX manufacture of to cells trial. them while collected program, successful to far individuals improvement site would investigation, XX injury addressing dry outcomes cord to right and is spinal later-stage an deliver in was has efficacy injury, to approach data tested of been due move and severe the we of Our this that before we basically
recently small safety test We in DOSED to area a will began study the to the performance first device. is study called in study of clinical are novel delivery The be delivery testing system original we the a device and X of superior We the improvement the delivery. believe ways.
a the device you new deliver stopping the when to easier X to stop it's patients sites.
And X to dose necessary to was clinical to Previously, minutes more perspiration. over it cells patient's use importantly, be cells. ventilation the of administered allows without First, and to deploy
So this enhancement is procedure. a the to significant
be is In important this chronic the be collecting investigate safety OPCX of time experimental which may is That and arise. performance administered which for represents because device, addition population study patients first this the patient gives to of patients, also on with an any a therapy. efficacy new will signals we all cord additional the the and injury, to assessments us the to will functional spinal that larger opportunity
expected UC is quarter. The the first study next down commence Diego enrollment is clinical patient San site just at to for and Health road this
they a OPCX. add the our and second either make should the still to from this lengthy has I immediate make. the occur is population. X area steps we soon increase We formulation, that so our which introduce When larger FDA, clinical new OpRegen a cells portfolio. we a endpoints, but with studies. improvement activities the a will overcome enhancements data subparts. The just dose which X will prior we required before issuances, future we, the of to we capture complexity actually X formulation relevant first begin In from And CIRM been trial patent that that cells, help don't think developed lessons of these to Subject purity is were necessary you to on trial. which to CIRM applications, highlight indicated a have with of scale, conduct from that on plan apply individual want improved for cells patient also has a spring.
Last working have our make continued new this the parallel a the partner, focus we clinical design believe clinically which aware, we the we these be DOSED this add And process design, grant or and larger applied and device in position second, concluded, we manufacturing accepting to process, the OPCX control new comment alone clearance value I as collecting plan of our to to preparation we financials are the review we program, all will of in as program ongoing more use eliminates patent to OPCX trial sensitive often obtaining the of in and with are the we into
For earlier covering certain included example, patents additional our manufacture cells. of X issued, this claims we year, OpRegen how which aspects
Some to discoveries the aim turn trade make, our in a in we we all for with But way.
And we that, of Jill while best of as increase intentionally position I will to over things secrets. our the patent, others development proprietary our possible we programs overall, retain financials. review OpRegen of for
